Introduction {#s1}
============

Lymphedema (LE) following treatment for breast cancer is the most common form of LE in the industrialized world [@pone.0060164-MabyElHajjami1]. LE is caused by a reduction in lymph transport capacity associated with the cancer and its treatment (e.g., surgery, radiation therapy (RT), chemotherapy (CTX)) and results in the accumulation of protein-rich fluid in the interstitial space. LE results in disfigurement, discomfort, and functional impairments. In addition, LE may precipitate cellulitis and lymphangitis [@pone.0060164-Stamatakos1].

The exact prevalence of LE in breast cancer survivors is unknown with estimates ranging from 3% to 87% [@pone.0060164-Armer1]. This wide variation is due to differences in measurement methods, inconsistencies in diagnostic criteria, as well as variations in sample characteristics, timing of measurements, and duration of follow-up. However, as noted by Armer [@pone.0060164-Armer1], if the incidence of LE is conservatively set at 20%, more than 500,000 breast cancer survivors in the United States are affected by this condition.

One of the major goals of LE research is the identification of women at greatest risk for the development of this condition following breast cancer treatment. Risk factors evaluated in the majority of studies done to date focused on patient, disease, and treatment characteristics. However, in four large scale prospective cohort studies [@pone.0060164-Kwan1]--[@pone.0060164-Dominick1], the factors associated with increased risk for LE were not concordant. In a study of 1,287 women (104 were diagnosed with LE) [@pone.0060164-Ahmed1], risk factors for LE included: higher stage of disease, increased number of lymph nodes removed, removal of tumor positive nodes, receipt of adjuvant CTX, higher body mass index (BMI), and poorer health status. In a second study of 997 women (133 had LE) [@pone.0060164-Kwan1], risk factors for LE included: being African American, being better educated, higher stage of disease, and removal of at least one lymph node. In a population-based sample of 631 women (237 had LE) [@pone.0060164-Norman1], hazard ratios for the development of LE were increased following axillary lymph node dissection (ALND) and receipt of CTX. Finally, in a sample of breast cancer patients (n = 2,431) from the Women\'s Healthy Eating and Living Well Study [@pone.0060164-Dominick1], women with LE (28.5% of the sample) were diagnosed at a younger age, had a higher BMI, had a larger tumor size, had more lymph nodes removed, were more likely to have a mastectomy with radiation therapy (RT) and were more likely to have CTX. While all four studies evaluated a large number of risk factors, the diagnosis of LE relied on patient self-report [@pone.0060164-Ahmed1]--[@pone.0060164-Dominick1] or medical record data [@pone.0060164-Kwan1].

While the phenotypic characterization of risk for LE following breast cancer treatment warrants additional investigation, recent evidence suggests that some of the variation in the occurrence and time to onset of LE may be related to genomic determinants [@pone.0060164-Finegold1], [@pone.0060164-Finegold2]. These two studies evaluated candidate genes that are known to play a role in lymphatic development [@pone.0060164-SchulteMerker1]--[@pone.0060164-Jurisic1] or were identified in studies of primary LE which are Mendelian inherited disorders. In a study that evaluated hepatocyte growth factor (HGF) and the high affinity hepatocyte growth factor receptor (MET) in 59 women with breast cancer related LE [@pone.0060164-Finegold2], mutations leading to truncation or missense changes in evolutionarily conserved residues of HGF and MET were identified. In a case control study of 188 women (80 diagnosed with LE) [@pone.0060164-Finegold1], mutations in GJC2 that encodes for connexin 47 were identified in women with LE. Taken together, these findings suggest that additional studies are warranted to determine the phenotypic and genotypic factors associated with increased risk for LE following breast cancer treatment. Therefore, the purposes of this study were to evaluate for differences in phenotypic and genotypic characteristics in women who did and did not develop LE following breast cancer treatment.

Methods {#s2}
=======

Study Samples and Procedures {#s2a}
----------------------------

Demographic, clinical, and genomic data from a cross-sectional study (i.e., LE Study (NR0101282)) and a longitudinal study (i.e., Breast Symptoms Study (CA107091 and CA118658)) were combined for these analyses. Both studies used the same subjective and objective measures. Both studies were approved by the UCSF Committee on Human Research and the CTSI Clinical Research Center Advisory Committee.

### LE Study {#s2a1}

The LE study used a cross-sectional design to evaluate for differences in phenotypic and genotypic characteristics in women with (n = 74) and without LE (n = 71). Women who were ≥18 years of age, ≥6 months post-treatment for unilateral breast cancer, and with or without upper extremity LE were recruited. Women were excluded for bilateral breast cancer, current upper extremity infection, lymphangitis, preexisting LE, current breast cancer, or contraindications to bioimpedance spectroscopy (BIS) testing. Women were recruited through the National Lymphedema Network website, San Francisco Bay area hospitals, and breast cancer or LE support groups and conferences. Women were evaluated in the Clinical Research Center at UCSF. After obtaining written informed consent, women completed the study questionnaires. Following the completion of the questionnaires, the research staff performed the objective measurements: height, weight, and BIS. A blood sample was drawn for genomic analyses.

### Breast Symptoms Study {#s2a2}

The Breast Symptoms Study used a prospective, longitudinal design to evaluate neuropathic pain and LE following breast cancer surgery. Women were recruited from Breast Care Centers located in a Comprehensive Cancer Center, two public hospitals, and four community practices. Patients were eligible to participate if they were: adult women (≥18 years) who would undergo breast cancer surgery on one breast; able to read, write, and understand English; agreed to participate, and gave written informed consent. Patients were excluded if they were: having breast cancer surgery on both breasts and/or had distant metastasis at the time of diagnosis. A total of 516 patients were approached to participate, 410 were enrolled in the study (response rate 79.4%), and 398 completed the preoperative assessment. The major reasons for refusal were: too busy, overwhelmed with the cancer diagnosis, or insufficient time available to do the baseline assessment prior to surgery. During the patient\'s preoperative visit, a clinician explained the study, determined the patient\'s willingness to participate, and introduced the patient to the research nurse. The research nurse met with the woman, determined eligibility, and obtained written informed consent prior to surgery.

After obtaining written informed consent, the patient completed the enrollment questionnaires prior to surgery. Following the completion of the questionnaires, the research nurse performed the objective measurements: height, weight, and BIS. A blood sample was drawn for genomic analyses. Patients were contacted two weeks after surgery to schedule the first post-surgical appointment. The research nurse met with the patients either in their home or in the Clinical Research Center at 1, 2, 3, 4, 5, 6, 8, 10, and 12 months after surgery. In the second through fifth years of the study, patients were seen every four months. During each of the study visits, the women completed the study questionnaires and had the objective measures done by the research nurse.

Subjective Measures {#s2b}
-------------------

A demographic questionnaire was used to obtain information on age, marital status, education, ethnicity, employment status, living situation, and financial status. Functional status was evaluated using the Karnofsky Performance Status (KPS) scale that has well established validity and reliability [@pone.0060164-Karnofsky1], [@pone.0060164-Karnofsky2]. Patients rated their functional status using the KPS scale that ranged from 30 (I feel severely disabled and need to be hospitalized) to 100 (I feel normal; I have no complaints or symptoms). Patients were asked to indicate if they exercised on a regular basis (yes/no). Clinical information was obtained from patient interviews and medical record reviews.

Self-Administered Comorbidity Questionnaire (SCQ) is a short and easily understood instrument that was developed to measure comorbidity in clinical and health service research settings [@pone.0060164-Sangha1]. The questionnaire consists of 13 common medical conditions that were simplified into language that could be understood without any prior medical knowledge. Patients were asked to indicate if they had the condition using a "yes/no" format. If they indicated that they had a condition, they were asked if they received treatment for it (yes/no; proxy for disease severity) and did it limit their activities (yes/no; indication of functional limitations). Patients were given the option to add two additional conditions not listed on the instrument. For each condition, a patient can receive a maximum of 3 points. Because there are 13 defined medical conditions and 2 optional conditions, the maximum score totals 45 points if the open-ended items are used and 39 points if only the closed-ended items are used. The SCQ has well-established validity and reliability and has been used in studies of patients with a variety of chronic conditions [@pone.0060164-Sangha1]--[@pone.0060164-Brunner1].

Objective Measures {#s2c}
------------------

### Bioimpedance Spectroscopy (BIS) of LE {#s2c1}

BIS measurements, of the affected and unaffected arm, were done using the procedures described by Cornish and colleagues [@pone.0060164-Hayes1]--[@pone.0060164-Cornish2]. Patients were instructed not to exercise or take a sauna within 8 hours of the assessment. In addition, they were asked to refrain from drinking alcohol for 12 hours prior to the assessment. BIS measurements were taken using a single channel BIS device (i.e., SFB7 device; ImpediMed, San Diego, CA in the LE study or the Quantum X Bioelectrical Impedance Device; RJL Systems, Clinton Township, MI in the Breast Symptoms Study). Women removed all jewelry and their skin was prepped with an alcohol wipe prior to surface electrode placement. Patients lay supine on a massage table with their arms 30 degrees from the body and legs not touching for at least 10 minutes prior to the BIS measurements. Electrodes were placed on the dorsum of the wrists adjacent to the ulnar styloid process, the dorsum of the hands just proximal to the third metacarpophalangeal joint, anterior to the ankle joints between the malleoli, and over the dorsum of the feet over the third metatarsal bone just proximal to the third metatarsophalangeal joint. Two 'measurement' electrodes were placed at either end of the 40 cm length over which the circumference measurements were made and the 'drive' electrodes were placed 8 to 10 cm distal to these measurement electrodes. These electrode sites were chosen, for the segmental measurement of the arm, in preference to the standard shoulder to wrist sites so that direct comparisons could be made between the volumes measured by the circumference method and by the BIS method. Two readings of resistance were obtained from the affected and unaffected arms and averaged for subsequent analyses.

While cases and non-cases of LE were known in the LE study, for the Breast Symptoms Study, LE cases were determined based on the procedures of Cornish and colleagues [@pone.0060164-Hayes1]--[@pone.0060164-Cornish2], using all of the data obtained from each woman during her participation in the study. A woman was defined as a LE case if the resistance ratio for the untreated arm/treated arm prior to surgery was \>1.139 or \>1.066 for those women who had surgery on the dominant or nondominant side, respectively at any of the BIS assessments.

Methods of Analysis for Phenotypic Data {#s2d}
---------------------------------------

Data were analyzed using SPSS Version 19 [@pone.0060164-SPSS1]. Descriptive statistics and frequency distributions were generated on the sample characteristics. Independent sample t-tests, Chi-square analyses, and Mann Whitney U tests were done to evaluate for differences in demographic, clinical, and genotypic characteristics between patients with and without LE. Logistic regression analyses were performed to evaluate the association between phenotypic characteristics and LE group membership.

Methods of Analysis for Genomic Data {#s2e}
------------------------------------

### Gene Selection {#s2e1}

Candidate genes for secondary LE include genes that cause monogenic (i.e., primary) forms of LE or genes that cause primary LE in animal models [@pone.0060164-Ferrell1]--[@pone.0060164-Saito1]. While the genetic causes of primary LE might be due to ablative mutations or variations in these candidate genes, secondary LE may be caused by modest functional variations that do not result in critical loss of gene function. Candidate genes for primary LE include angiopoeitin-2 (ANGPT2), elastin microfibril interfacer (EMILIN1), Forkhead box protein C2 (FOXC2), hepatocye growth factor (HGF), lymphocyte cytosolic protein 2 (LCP2), lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1, XLKD1), hepatocyte growth factor receptor (MET), neuropilin-2 (NRP2), Prospero-related homeobox 1 (PROX1), ROR orphan receptor C (RORC), SpSRY-box 17 (SOX17), protein tyrosine kinase (SYK), vascular cell adhesion molecule 1 (VCAM1), and vascular endothelial growth factor-B (VEGFB), -C (VEGFC), -D (VEGFD), -receptor 2 (VEGFR2), and -receptor 3 (VEGFR3).

### Blood collection and genotyping {#s2e2}

Genomic DNA was extracted from archived buffy coats using the PUREGene DNA Isolation System (Invitrogen, Carlsbad, CA). Of the 543 patients recruited for this study, DNA was recovered from the archive buffy coat of 407 patients (i.e., 110 with and 297 without LE) who provided a blood sample. No differences were found in any demographic and clinical characteristics between patients who did and did not choose to participate in the studies or between those patients who did and did not provide a blood sample for genomic analyses.

Genotyping was performed blinded to LE status and positive and negative controls were included. DNA was quantitated with a Nanodrop Spectrophotometer (ND-1000) and normalized to a concentration of 50 ng/μL (diluted in 10 mM Tris/1 mM EDTA). Samples were genotyped using the GoldenGate genotyping platform (Illumina, San Diego, CA) and processed according to the standard protocol using GenomeStudio (Illumina, San Diego, CA). Signal intensity profiles and resulting genotype calls for each single nucleotide polymorphism (SNP) were visually inspected by two blinded reviewers. Disagreements were adjudicated by a third reviewer.

### SNP Selection {#s2e3}

A combination of tagging SNPs and literature driven SNPs (i.e., SNPs reported as being associated with LE) were selected for analysis. Tagging SNPs were required to be common (i.e., estimated to have a minor allele frequency ≥.05) in public databases (e.g., HapMap). In order to ensure robust genetic association analyses, quality control filtering of SNPs was performed. SNPs with call rates of \<95% or Hardy-Weinberg p-values of \<.001 were excluded.

As shown in [Table 1](#pone-0060164-t001){ref-type="table"}, a total of 157 SNPs among the 17 candidate genes (ANGPT2: 25 SNPs, FOXC2: 3 SNPs; HGF: 3 SNPs; LCP2: 11 SNPs; LYVE1: 1 SNP; MET: 15 SNPs; NRP2: 32 SNPs; PROX1: 3 SNPs; RORC: 4 SNPs; SOX17:1 SNP; SYK: 19 SNPs; VCAM1: 7 SNPs; VEGFB: 1 SNP; VEGFC: 8 SNPs; VEGFD: 4 SNPs; VEGFR2: 12 SNPs, VEGFR3: 8 SNPs) passed all quality control filters and were included in the genetic association analyses. The one SNP used to evaluate genetic variation in EMILIN1 did not pass the quality control filters. Potential functional roles of SNPs associated with LE were examined using PUPASuite 2.0 [@pone.0060164-Conde1], a comprehensive search engine that predicts a series of functional effects (i.e., non-synonymous changes, altered transcription factor binding sites, exonic splicing enhancing or silencing, splice site alterations, microRNA target alterations).
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###### Lymphatic and angiogenic genes and single nucleotide polymorphisms analyzed for lymphedema versus no lymphedema.

![](pone.0060164.t001){#pone-0060164-t001-1}

  Gene         SNP       Position    Chr     MAF     Alleles               Chi Square                p-value   Model
  -------- ------------ ----------- ----- --------- --------- ------------------------------------- --------- -------
  ANGPT2    rs2916716     6344643     8     .287      T\>A                    .380                    .827       A
  ANGPT2    rs2442468     6351358     8     .493      G\>C                    .073                    .964       A
  ANGPT2    rs2515409     6352330     8     .146      T\>C                    .131                    .937       A
  ANGPT2    rs2515413     6353028     8     .205      T\>C                    1.464                   .481       A
  ANGPT2    rs2442636     6354369     8     .446      T\>C                    .346                    .841       A
  ANGPT2    rs2442631     6356184     8     .428      G\>A                    .096                    .953       A
  ANGPT2    rs1982386     6358884     8     .314      G\>A                    .542                    .762       A
  ANGPT2    rs2515462     6371007     8     .287      G\>A                    2.660                   .264       A
  ANGPT2    rs6990020     6373612     8     .380      T\>C                     FE                     .040       D
  ANGPT2    rs2515466     6373694     8     .231      G\>A                    .230                    .892       A
  ANGPT2    rs2442608     6374028     8     .447      A\>G                    .985                    .611       A
  ANGPT2     rs734701     6375655     8     .329      T\>C                    1.570                   .456       A
  ANGPT2    rs2515477     6376048     8     .131      C\>T                    .904                    .636       A
  ANGPT2    rs12674822    6376624     8     .440      G\>T                    .865                    .649       A
  ANGPT2    rs2515483     6379677     8     .353      G\>C                    .644                    .725       A
  ANGPT2    rs17552444    6381587     8     .269      A\>G                    .731                    .694       A
  ANGPT2    rs11989215    6383317     8     .338      A\>G                    .371                    .831       A
  ANGPT2    rs11989242    6383428     8     .478      G\>A                    .567                    .753       A
  ANGPT2    rs11137037    6383590     8     .326      A\>C                    3.009                   .222       A
  ANGPT2    rs17623313    6383749     8     .431      C\>T                    .150                    .928       A
  ANGPT2    rs13269021    6384171     8     .270      G\>T                    .176                    .916       A
  ANGPT2    rs1823375     6384406     8     .349      C\>G                    1.537                   .464       A
  ANGPT2    rs13255574    6386085     8     .204      C\>T                    .208                    .901       A
  ANGPT2    rs2922869     6387201     8     .349      A\>G                    1.543                   .462       A
  ANGPT2    rs2515488     6390414     8     .458      A\>C                    2.811                   .245       A
              HapA04                                                          .119                    .942    
              HapA06                                                          .533                    .766    
              HapB01                                                          .093                    .955    
              HapB04                                                          .203                    .903    
              HapC01                                                          3.938                   .140    
              HapC04                                                          2.438                   .295    
              HapD01                                                          1.570                   .456    
              HapD02                                                          1.087                   .581    
              HapD03                                                          .797                    .671    
              HapE01                                                          1.816                   .403    
              HapE02                                                          .682                    .711    
              HapE03                                                          .860                    .650    
              HapF01                                                          3.375                   .185    
              HapF07                                                          .158                    .924    
              HapG01                                                          .677                    .713    
              HapG02                                                          1.392                   .499    
              HapG03                                                          .295                    .863    
              HapH02                                                          1.523                   .467    
              HapH03                                                          .202                    .904    
  FOXC2     rs34221221   85157931    16     .452      T\>C                    2.830                   .243       A
  FOXC2     rs11640590   85159945    16    *0.000*    C\>A     All patients were homozygous for CC            
  FOXC2     rs1035550    85160208    16     .087      C\>T                    3.934                   .140       A
              HapA01                                                          2.830                   .243    
              HapA03                                                          6.214                   .045    
  HGF       rs5745692    81196202     7    .*033*     G\>C                     n/a                     n/a      n/a
  HGF        rs757830    81200320     7     .221      T\>C                    1.998                   .368       A
  HGF       rs5745616    81236292     7     .222      G\>A                    1.315                   .518       A
  LCP2      rs3789184    169611615    5     .494      T\>C                    2.794                   .247       A
  LCP2       rs572192    169621175    5     .410      A\>G                     FE                     .047       D
  LCP2      rs10475933   169622825    5     .285      C\>T                    .409                    .815       A
  LCP2      rs2338872    169625132    5     .366      A\>G                    1.492                   .474       A
  LCP2       rs315745    169630285    5     .459      T\>C                    .431                    .806       A
  LCP2      rs2271146    169634968    5     .466      G\>T                    .119                    .942       A
  LCP2      rs2338873    169641269    5     .141      G\>A                    3.164                   .206       A
  LCP2       rs315721    169647616    5     .305      A\>G                     FE                     .005       D
  LCP2       rs182618    169655691    5     .278      A\>G                    4.040                   .133       A
  LCP2      rs6866733    169655807    5     .197      C\>T                     FE                     .026       D
  LCP2       rs315730    169656902    5     .434      A\>T                    .644                    .725       A
              HapA03                                                          .510                    .775    
              HapA04                                                          4.304                   .116    
  LYVE1     rs17318858   10536263    11     .176      T\>C                    .547                    .761       A
  MET        rs714180    116106238    7     .488      G\>A                    .981                    .612       A
  MET        rs38841     116107162    7     .362      A\>G                    .001                    1.000      A
  MET        rs39747     116108275    7     .441      T\>C                    2.782                   .249       A
  MET        rs38845     116109038    7     .456      G\>A                    4.550                   .103       A
  MET        rs39748     116114666    7     .442      G\>C                    1.177                   .555       A
  MET        rs38849     116119775    7     .249      G\>C                    2.414                   .299       A
  MET       rs2237710    116124588    7     .289      T\>G                    1.666                   .435       A
  MET        rs38850     116124885    7     .246      G\>A                    2.491                   .288       A
  MET       rs11762213   116126518    7     .053      G\>A                    1.434                   .488       A
  MET       rs2299437    116128724    7     .244      G\>A                    1.244                   .537       A
  MET        rs38857     116152649    7     .275      C\>T                    1.954                   .376       A
  MET       rs2402118    116215809    7     .338      C\>A                    1.915                   .384       A
  MET        rs193686    116218663    7     .287      T\>C                    1.569                   .456       A
  MET       rs2023748    116223258    7     .447      G\>A                    2.968                   .227       A
  MET         rs1621     116224842    7     .318      A\>G                    1.909                   .385       A
              HapA01                                                          2.427                   .297    
              HapA03                                                          4.016                   .134    
              HapB02                                                          2.545                   .280    
              HapC02                                                          3.296                   .192    
              HapC06                                                          1.704                   .427    
              HapC07                                                          2.003                   .367    
  NRP2      rs1517527    206252547    2     .408      C\>T                    1.126                   .569       A
  NRP2      rs6711044    206252910    2     .479      T\>C                    .413                    .813       A
  NRP2      rs1400733    206253168    2     .432      C\>G                    .329                    .848       A
  NRP2      rs3806577    206254395    2     .412      A\>G                    .291                    .865       A
  NRP2       rs861078    206260223    2     .351      A\>G                    1.320                   .517       A
  NRP2       rs849530    206264049    2     .482      T\>G                     FE                     .042       R
  NRP2       rs950219    206268858    2     .308      G\>A                    3.601                   .165       A
  NRP2      rs3771052    206269672    2     .293      G\>A                    2.566                   .272       A
  NRP2       rs849556    206271503    2     .305      G\>A                    1.858                   .395       A
  NRP2       rs863707    206284428    2     .445      T\>G                    .678                    .712       A
  NRP2       rs849525    206301486    2     .466      G\>A                    .635                    .728       A
  NRP2      rs3771033    206304055    2     .326      G\>A                    3.654                   .161       A
  NRP2       rs849523    206304181    2     .279      C\>T                    1.299                   .522       A
  NRP2      rs1983343    206304908    2     .343      A\>G                    1.258                   .533       A
  NRP2       rs849584    206309961    2     .318      G\>T                    2.925                   .232       A
  NRP2      rs3771021    206318233    2     .405      C\>T                    .723                    .697       A
  NRP2       rs849563    206318747    2     .187      A\>C                     FE                     .012       R
  NRP2      rs1996412    206320830    2     .473      A\>G                    4.227                   .121       A
  NRP2      rs2241156    206323209    2     .358      G\>C                    1.564                   .457       A
  NRP2      rs2241155    206323311    2     .358      C\>T                    .293                    .864       A
  NRP2      rs3771016    206323784    2     .418      G\>A                    .005                    .998       A
  NRP2      rs3771010    206331839    2     .477      G\>C                    .219                    .896       A
  NRP2       rs867344    206335660    2     .346      C\>T                    .783                    .676       A
  NRP2      rs3771004    206339132    2     .305      G\>A                    .006                    .997       A
  NRP2      rs16837637   206339499    2     .402      G\>A                    .417                    .812       A
  NRP2      rs16837641   206343114    2     .371      G\>A                     FE                     .009       R
  NRP2      rs2241153    206344368    2     .383      G\>T                    1.748                   .417       A
  NRP2      rs2160328    206350582    2     .374      C\>T                    2.150                   .341       A
  NRP2      rs4675542    206353492    2     .213      G\>C                    1.940                   .379       A
  NRP2      rs10932125   206360545    2     .456      G\>C                    3.922                   .141       A
  NRP2      rs3755232    206361208    2     .253      A\>G                    3.096                   .213       A
  NRP2       rs15994     206370542    2     .377      C\>G                    1.106                   .575       A
              HapA01                                                          5.793                   .055    
              HapA06                                                          2.709                   .258    
              HapB01                                                          3.427                   .180    
              HapB04                                                          .631                    .730    
              HapB05                                                          1.340                   .512    
              HapC01                                                          .163                    .922    
              HapC02                                                          .367                    .832    
              HapC03                                                          3.431                   .180    
              HapD01                                                          .137                    .934    
              HapD06                                                          .430                    .807    
              HapE01                                                          3.083                   .214    
              HapE02                                                          .372                    .830    
              HapE03                                                          .006                    .997    
              HapF01                                                          8.937                   .011    
              HapF03                                                          1.574                   .455    
              HapF06                                                          1.426                   .490    
  PROX1      rs340874    212225879    1     .499      A\>G                    1.919                   .383       A
  PROX1      rs340839    212228443    1     .483      C\>T                    2.961                   .227       A
  PROX1      rs726334    212246741    1     .284      C\>T                    .726                    .696       A
  RORC        rs9826     150045523    1     .371      A\>G                    .097                    .953       A
  RORC       rs939595    150050312    1     .381      C\>A                    .232                    .891       A
  RORC      rs7540530    150057482    1     .466      G\>A                    .420                    .811       A
  RORC      rs11204894   150059798    1     .225      G\>T                    3.952                   .139       A
              HapA01                                                          .420                    .811    
              HapA03                                                          .624                    .732    
              HapA06                                                          4.005                   .135    
  SOX17     rs12541742   55533707    10     .210      C\>T                     FE                     .008       D
  SYK       rs1319677    92605820     9     .484      T\>C                    .171                    .918       A
  SYK       rs1333633    92607393     9     .416      T\>C                    .835                    .659       A
  SYK       rs3789889    92611162     9     .339      A\>G                    2.008                   .366       A
  SYK        rs290237    92614471     9     .204      A\>G                    .034                    .983       A
  SYK       rs4744505    92619818     9     .391      G\>A                    .140                    .932       A
  SYK       rs2065583    92632383     9     .151      G\>C                    1.174                   .556       A
  SYK        rs290213    92635628     9     .143      A\>G                    1.116                   .572       A
  SYK       rs1870660    92637826     9     .163      C\>G                    .682                    .711       A
  SYK       rs1864202    92641776     9     .261      C\>A                    2.573                   .276       A
  SYK       rs17489214   92642959     9     .186      G\>A                    .342                    .843       A
  SYK       rs2035073    92649240     9     .328      T\>C                    .093                    .955       A
  SYK       rs11787537   92656440     9     .185      G\>A                    .576                    .750       A
  SYK       rs10993726   92660569     9     .214      C\>T                    .678                    .713       A
  SYK       rs9695993    92663585     9     .123      A\>C                    .742                    .690       A
  SYK        rs290229    92674234     9     .259      C\>T                    3.746                   .154       A
  SYK       rs10761395   92682718     9     .300      T\>C                    2.009                   .366       A
  SYK        rs290254    92691706     9     .408      G\>C                    .078                    .962       A
  SYK        rs158689    92697582     9     .456      A\>T                     FE                     .039       R
  SYK       rs1049164    92698027     9     .178      G\>A                    2.849                   .241       A
              HapA01                                                          .204                    .903    
              HapA04                                                          .688                    .709    
              HapB01                                                          .617                    .735    
              HapB02                                                          .161                    .923    
              HapB03                                                          .029                    .985    
              HapC01                                                          1.608                   .448    
              HapD01                                                          9.769                   .008    
              HapD03                                                          .093                    .955    
              HapE01                                                          3.746                   .154    
              HapE02                                                          .024                    .988    
              HapE03                                                          2.009                   .366    
              HapF01                                                          5.000                   .082    
              HapF03                                                          5.254                   .072    
  VCAM1     rs1409419    100955984    1     .498      T\>C                    1.095                   .578       A
  VCAM1     rs3176860    100959807    1     .412      A\>G                    .880                    .644       A
  VCAM1     rs3176861    100959909    1     .201      C\>T                     FE                     .036       D
  VCAM1     rs3917012    100968247    1     .350      T\>G                    3.381                   .184       A
  VCAM1     rs3181088    100971296    1     .167      C\>T                    1.520                   .468       A
  VCAM1     rs3176877    100975983    1     .396      T\>A                    2.366                   .306       A
  VCAM1     rs3176879    100976415    1     .061      A\>G                    1.579                   .454       A
              HapA01                                                          1.579                   .454    
              HapA05                                                          .825                    .662    
              HapB01                                                          8.241                   .016    
              HapB02                                                          2.366                   .306    
  VEGFB     rs3741403    63756105    11     .433      G\>A                    .553                    .759       A
  VEGFC     rs1485762    177844725    4     .310      C\>T                    5.000                   .082       A
  VEGFC     rs7664413    177845701    4     .206      C\>T                    6.364                   .041       A
  VEGFC     rs6828869    177847127    4     .451      C\>G                    .329                    .848       A
  VEGFC     rs1485766    177847878    4     .469      A\>C                    .219                    .896       A
  VEGFC     rs3775202    177848205    4     .494      A\>G                    2.226                   .329       A
  VEGFC     rs3775195    177858104    4     .238      C\>A                    1.112                   .573       A
  VEGFC     rs3775194    177860871    4     .407      C\>G                    .482                    .786       A
  VEGFC     rs1485765    177864946    4     .156      A\>G                    1.453                   .484       A
              HapA01                                                          .297                    .862    
              HapA05                                                          6.173                   .046    
              HapB01                                                          2.463                   .292    
              HapB03                                                          7.194                   .027    
              HapB04                                                          1.254                   .534    
  VEGFD     rs6527518    15276100     X     .435      G\>T                    .009                    .996       A
  VEGFD     rs6418686    15297927     X     .329      T\>C                    .116                    .944       A
  VEGFD     rs4830939    15309204     X     .324      G\>A                    .182                    .913       A
  VEGFD     rs6632528    15312319     X     .258      T\>C                    .264                    .876       A
              HapA01                                                          .001                    .999    
              HapA02                                                          .474                    .789    
              HapA03                                                          .325                    .850    
  VEGFR2    rs12642307   55646938     4     .256      T\>C                    2.524                   .283       A
  VEGFR2    rs1531289    55649989     4     .288      G\>A                    .111                    .946       A
  VEGFR2    rs7671745    55651593     4     .329      G\>A                    .557                    .757       A
  VEGFR2    rs6828477    55661558     4     .398      T\>C                    .801                    .670       A
  VEGFR2    rs2168945    55662240     4     .327      T\>G                    1.008                   .604       A
  VEGFR2    rs1870377    55667731     4     .254      T\>A                    3.543                   .170       A
  VEGFR2    rs2034965    55672557     4     .278      G\>A                    .923                    .630       A
  VEGFR2    rs11941492   55672967     4     .243      C\>T                    2.307                   .316       A
  VEGFR2    rs10020464   55673827     4     .330      C\>T                     FE                     .025       D
  VEGFR2    rs11133360   55677509     4     .455      T\>C                     FE                     .032       R
  VEGFR2    rs1531290    55681319     4     .437      A\>G                    .836                    .658       A
  VEGFR2    rs12502008   55685799     4     .397      G\>T                    1.751                   .417       A
              HapA01                                                          .386                    .825    
              HapA02                                                          .604                    .739    
              HapA03                                                          .111                    .946    
              HapB02                                                          3.331                   .189    
              HapB03                                                          1.096                   .578    
              HapB04                                                          .716                    .699    
              HapC01                                                          4.155                   .125    
              HapC03                                                          .278                    .870    
              HapC04                                                          7.730                   .021    
  VEGFR3    rs2242216    179974097    5     .430      G\>A                    .137                    .934       A
  VEGFR3     rs400330    179974268    5     .375      T\>C                    .274                    .872       A
  VEGFR3     rs307823    179984714    5     .271      A\>G                    1.617                   .446       A
  VEGFR3    rs3797102    179987794    5     .392      T\>C                    .255                    .880       A
  VEGFR3    rs2290983    179991569    5     .453      T\>C                    .708                    .702       A
  VEGFR3    rs10085109   179993410    5    .*484*     C\>G                     n/a                     n/a      n/a
  VEGFR3    rs11748431   180001347    5     .237      G\>A                    2.704                   .259       A
  VEGFR3     rs307814    180006854    5     .387      C\>T                    .179                    .914       A
              HapA01                                                          .276                    .871    
              HapA03                                                          .137                    .934    
              HapB02                                                           FE                     .643    
              HapB03                                                          3.693                   .158    
              HapB04                                                          .453                    .797    
              HapC01                                                          .556                    .757    
              HapC02                                                          3.163                   .206    
              HapC03                                                          .490                    .783    

Abbreviations: A =  Additive model; ANGPT2  =  angiopoeitin-2; Chr  =  chromosome; D =  Dominant model; FOXC2 -- forkhead box C2; HGF  =  hepatocyte growth factor; LCP2  =  lymphocyte cytosolic protein 2; LYVE1  =  lymphatic vessel endothelial hyaluronan receptor 1 (XLKD1); MAF  =  minor allele frequency; MET  =  hepatocyte growth factor receptor; n/a  =  not assayed because SNP violated Hardy-Weinberg expectations (p\<.001); NRP2 -- neuropilin-2; PROX1  =  prospero-related homeobox 1; R =  Recessive model; RORC  =  ROR orphan receptor C; SNP  =  single nucleotide polymorphism; SOX17  =  SpSRY-box 17; SYK  =  protein tyrosine kinase; VCAM1  =  vascular cell adhesion molecule 1; VEGFB  =  vascular endothelial growth factor B; VEGFC  =  vascular endothelial growth factor C; VEGFD  =  vascular endothelial growth factor D; VEGFR2  =  vascular endothelial growth factor receptor 2; VEGFR3  =  vascular endothelial growth factor receptor 3.

### Statistical Analyses {#s2e4}

Allele and genotype frequencies were determined by gene counting. Hardy-Weinberg equilibrium was assessed by the Chi-square or Fisher Exact tests. Measures of linkage disequilibrium ((LD) i.e., D\' and r^2^) were computed from the participants\' genotypes with Haploview 4.2. LD-based haplotype block definition was based on D\' confidence interval [@pone.0060164-Gabriel1].

For SNPs that were members of the same haploblock, haplotype analyses were conducted in order to localize the association signal within each gene and to determine if haplotypes improved the strength of the association with the phenotype. Haplotypes were constructed using the program PHASE version 2.1 [@pone.0060164-Stephens1]. In order to improve the stability of haplotype inference, the haplotype construction procedure was repeated five times using different seed numbers with each cycle. Only haplotypes that were inferred with probability estimates of ≥.85, across the five iterations, were retained for downstream analyses. Haplotypes were evaluated assuming a dosage model (i.e., analogous to the additive model).

Ancestry informative markers (AIMS) were used to minimize confounding due to population stratification [@pone.0060164-Halder1]--[@pone.0060164-Tian1]. Homogeneity in ancestry among participants was verified by principal component analysis [@pone.0060164-Price1], using Helix Tree (Golden Helix, Bozeman, MT). Briefly, the number of principal components (PCs) was sought which distinguished the major racial/ethnic groups in the sample by visual inspection of scatter plots of orthogonal PCs (i.e., PC 1 versus PC2, PC2 versus PC3). This procedure was repeated until no discernible clustering of patients by their self-reported race/ethnicity was possible (data not shown). One hundred and six AIMs were included in the analysis. The first three PCs were selected to adjust for potential confounding due to population substructure (i.e., race/ethnicity) by including the three covariates in all regression models.

For association tests, three genetic models were assessed for each SNP: additive, dominant, and recessive. Barring trivial improvements (i.e., delta \<10%), the genetic model that best fit the data, by maximizing the significance of the p-value, was selected for each SNP. Logistic regression analysis, that controlled for significant covariates, as well as genomic estimates of and self-reported race/ethnicity, was used to evaluate the association between genotype and LE group membership. A backwards stepwise approach was used to create the most parsimonious model. Genetic model fit and both unadjusted and covariate-adjusted odds ratios were estimated using STATA version 9 [@pone.0060164-StataCorp1].

As was done in our previous studies [@pone.0060164-Illi1]--[@pone.0060164-Miaskowski1], based on recommendations in the literature [@pone.0060164-Rothman1], [@pone.0060164-Hattersley1], the implementation of rigorous quality controls for genomic data, the non-independence of SNPs/haplotypes in LD, and the exploratory nature of the analyses, adjustments were not made for multiple testing. In addition, significant SNPs identified in the bivariate analyses were evaluated further using regression analyses that controlled for differences in phenotypic characteristics, potential confounding due to population stratification, and variation in other SNPs/haplotypes within the same gene. Only those SNPs that remained significant were included in the final presentation of the results. Therefore, the significant independent associations reported are unlikely to be due solely to chance. Unadjusted (bivariate) associations are reported for all SNPs passing quality control criteria in [Table 1](#pone-0060164-t001){ref-type="table"} to allow for subsequent comparisons and meta-analyses.

Results {#s3}
=======

Differences in demographic and clinical characteristics {#s3a}
-------------------------------------------------------

As shown in [Table 2](#pone-0060164-t002){ref-type="table"}, no differences were found between patients with and without LE for the majority of the demographic and clinical characteristics. Patients with LE had a significantly higher BMI and a lower KPS score, and were more likely to report lung disease. In addition, patients with LE had a higher number of lymph nodes removed, a higher number of positive nodes, more advanced disease at the time of diagnosis, were less likely to have had a SLNB, and were more likely to have had an ALND, had received CTX prior to or following surgery, and had received RT following surgery.

10.1371/journal.pone.0060164.t002

###### Differences in demographic and clinical characteristics between patients with (n = 155) and without (n = 387) lymphedema.
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  Characteristic                        No Lymphedema   Lymphedema    Statistics
  ------------------------------------ --------------- ------------- ------------
  Age (years)                            54.9 (11.1)    56.2 (10.8)       NS
  Education (years)                      16.0 (2.7)     15.8 (2.8)        NS
  Age at menopause (years)               47.8 (7.2)     46.7 (9.1)        NS
  Body mass index (kg/m^2^)              26.1 (5.6)     28.2 (6.7)     p = .001
  Karnofsky Performance Status score     93.3 (9.7)     91.1 (11.1)    p = .028
  Comorbidity score                       4.0 (2.9)      4.5 (3.3)        NS
  Number of nodes removed                 5.8 (6.3)     10.9 (9.0)     p\<.0001
  Number of positive nodes                0.7 (1.7)      1.7 (3.4)     p = .009

                                                                                                                                                           \% (n)       \% (n)    
  ----------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ------------ ----------
  Ethnicity                                                                                                                                                                       
  White                                                                                                                                                  68.8 (265)   72.9 (113)  
  Black                                                                                                                                                   7.5 (29)     9.7 (15)       NS
  Asian/Pacific Islander                                                                                                                                 13.0 (50)     7.1 (11)   
  Hispanic/Mixed ethnic background/Other                                                                                                                 10.6 (41)    10.3 (16)   
  Lives alone                                                                                                                                                                     
  Yes                                                                                                                                                    23.0 (88)    28.9 (44)       NS
  No                                                                                                                                                     77.0 (295)   71.1 (108)  
  Married/partnered                                                                                                                                                               
  Yes                                                                                                                                                    47.4 (182)   52.0 (79)       NS
  No                                                                                                                                                     52.6 (202)   48.0 (73)   
  Employed                                                                                                                                                                        
  Yes                                                                                                                                                    51.4 (197)   49.7 (76)       NS
  No                                                                                                                                                     48.6 (186)   50.3 (77)   
  Handedness                                                                                                                                                                      
  Right                                                                                                                                                  88.8 (341)   88.9 (136)  
  Left                                                                                                                                                    8.1 (31)     9.2 (14)       NS
  Both                                                                                                                                                    3.1 (12)     2.0 (3)    
  Occurrence of comorbid conditions (% and number of women who reported each comorbid condition from the Self-Administered Comorbidity Questionnaire)                             
  Heart disease                                                                                                                                           5.6 (21)     6.0 (9)        NS
  High blood pressure                                                                                                                                    27.0 (103)   34.9 (53)       NS
  Lung disease                                                                                                                                            3.7 (14)     8.1 (12)    p = .04
  Diabetes                                                                                                                                                6.6 (25)     7.4 (11)       NS
  Ulcer                                                                                                                                                   3.7 (14)     4.7 (7)        NS
  Kidney disease                                                                                                                                          1.6 (6)      2.0 (3)        NS
  Liver disease                                                                                                                                           2.1 (8)      4.8 (7)        NS
  Anemia                                                                                                                                                  7.2 (27)     9.5 (14)       NS
  Depression                                                                                                                                             21.8 (81)    26.7 (39)       NS
  Osteoarthritis                                                                                                                                         19.2 (72)    26.7 (40)       NS
  Back pain                                                                                                                                              29.3 (110)   31.5 (47)       NS
  Rheumatoid arthritis                                                                                                                                    3.5 (13)     4.7 (7)        NS
  Diagnosed with mastitis                                                                                                                                                         
  Yes                                                                                                                                                    13.1 (50)    11.3 (17)       NS
  No                                                                                                                                                     86.9 (332)   88.7 (134)  
  Diagnosed with cystic breast disease                                                                                                                                            
  Yes                                                                                                                                                    21.5 (81)    23.3 (34)       NS
  No                                                                                                                                                     78.5 (295)   76.7 (112)  
  Breastfed                                                                                                                                                                       
  Yes                                                                                                                                                    49.4 (190)   45.1 (69)       NS
  No                                                                                                                                                     50.6 (195)   54.9 (84)   
  Surgery on affected breast not related to cancer                                                                                                                                
  Yes                                                                                                                                                     9.3 (36)    14.8 (23)       NS
  No                                                                                                                                                     90.7 (351)   85.2 (132)  
  Surgery to the affected arm not related to cancer                                                                                                                               
  Yes                                                                                                                                                     3.1 (12)     5.2 (8)        NS
  No                                                                                                                                                     96.9 (375)   94.8 (147)  
  Surgery on the affected hand not related to cancer                                                                                                                              
  Yes                                                                                                                                                     5.2 (20)     7.1 (11)       NS
  No                                                                                                                                                     94.8 (367)   92.9 (144)  
  Injury to the affected arm                                                                                                                                                      
  Yes                                                                                                                                                    17.3 (67)    22.6 (35)       NS
  No                                                                                                                                                     82.7 (320)   77.4 (120)  
  Injury to the affected hand                                                                                                                                                     
  Yes                                                                                                                                                    17.1 (66)    17.4 (27)       NS
  No                                                                                                                                                     82.9 (321)   82.6 (128)  
  Side of cancer surgery                                                                                                                                                          
  Dominant                                                                                                                                               49.9 (193)   41.9 (65)       NS
  Nondominant                                                                                                                                            50.1 (194)   58.1 (90)   
  Type of surgery                                                                                                                                                                 
  Breast conservation                                                                                                                                    75.2 (291)   70.3 (109)      NS
  Mastectomy                                                                                                                                             24.8 (96)    29.7 (46)   
  Stage of disease                                                                                                                                                                
  Stage 0                                                                                                                                                18.1 (70)     5.2 (8)    
  Stage I                                                                                                                                                40.1 (155)   32.9 (51)    p\<.0001
  Stage IIA and IIB                                                                                                                                      35.4 (137)   48.4 (75)   
  Stage IIIA, IIIB, IIIC, and IV                                                                                                                          6.5 (25)    13.5 (21)   
  Sentinel lymph node biopsy                                                                                                                                                      
  Yes                                                                                                                                                    80.9 (313)   69.7 (108)   p = .006
  No                                                                                                                                                     19.1 (74)    30.3 (47)   
  Axillary lymph node dissection                                                                                                                                                  
  Yes                                                                                                                                                    39.3 (152)   69.3 (106)   p\<.0001
  No                                                                                                                                                     60.7 (235)   30.7 (47)   
  Reconstruction at the time of surgery                                                                                                                                           
  Yes                                                                                                                                                    21.6 (68)    22.2 (18)       NS
  No                                                                                                                                                     78.4 (247)   77.8 (63)   
  Adjuvant chemotherapy                                                                                                                                                           
  Yes                                                                                                                                                    36.7 (142)   59.7 (92)    p\<.0001
  No                                                                                                                                                     63.3 (245)   40.3 (62)   
  Adjuvant radiation therapy                                                                                                                                                      
  Yes                                                                                                                                                    57.1 (221)   71.0 (110)   p\<.0001
  No                                                                                                                                                     42.9 (166)   29.0 (45)   
  Combinations of treatments                                                                                                                                                      
  Only surgery                                                                                                                                           23.8 (92)     8.4 (13)   
  Surgery and radiation therapy                                                                                                                          39.5 (153)   32.3 (50)    p\<.0001
  Surgery and chemotherapy                                                                                                                               19.1 (74)    20.6 (32)   
  Surgery, radiation therapy, and chemotherapy                                                                                                           17.6 (68)    38.7 (60)   
  Exercise on a regular basis                                                                                                                                                     
  Yes                                                                                                                                                    73.7 (283)   75.2 (115)      NS
  No                                                                                                                                                     26.3 (101)   24.8 (38)   

Abbreviations: kg  =  kilograms, m^2^ -- meter squared, NS  =  not significant, SD  =  standard deviation.

Regression analyses for phenotypic predictors of LE {#s3b}
---------------------------------------------------

As shown in [Table 3](#pone-0060164-t003){ref-type="table"}, two regression analyses were done to evaluate the associations between phenotypic characteristics and LE group membership. In the first regression analysis, that included BMI, stage of disease, SLNB status, number of lymph nodes removed, receipt of CTX, and receipt of RT predicted 13.8% of the variance in LE group membership (p\<0.0001). The odds of developing LE increased significantly for women who had a higher BMI, had a higher stage of disease at diagnosis, had a higher number of lymph nodes removed, had received CTX prior to or following surgery, and had received RT. The odds of having LE decrease significantly in women who had a SLNB.

10.1371/journal.pone.0060164.t003

###### Multiple logistic regression analyses for phenotypic predictors of the development of lymphedema.
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  Regression analysis WITHOUT the inclusion of genomic and self-reported race/ethnicity                                                                                                   
  --------------------------------------------------------------------------------------- ---------------- ------------------- ----------------------------------------- ---------------- -------------------
  BMI                                                                                           1.06              0.018                      1.025, 1.097                      3.39              0.001
  Stage of disease Stage 0 versus I Stage 0 versus II Stage 0 versus III and IV            3.23 3.18 3.62   1.590 1.622 2.151   1.234, 8.479 1.171, 8.640 1.129, 11.603   2.39 2.27 2.16   0.017 0.023 0.030
  SLNB                                                                                          0.42              0.116                      0.243, 0.719                     −3.16              0.002
  Number of nodes removed                                                                       1.06              0.017                      1.028, 1.093                      3.70             \<.0001
  Any chemotherapy                                                                              1.74              0.416                      1.086, 2.779                      2.30              0.021
  Any radiation therapy                                                                         1.94              0.452                      1.224, 3.060                      2.83              0.005
  Overall model fit: χ^2^ = 85.32, p\<0.0001, R^2^ = 0.1380                                                                                                                               

  Regression analysis WITH the inclusion of genomic and self-reported race/ethnicity                                                                                                                                    
  ------------------------------------------------------------------------------------------------------------------ ---------------- ------------------- ------------------------------------------ ------------------ -------------------
  BMI                                                                                                                      1.05              0.022                       1.012, 1.099                       2.56               0.010
  Stage of disease Stage 0 versus I Stage 0 versus II Stage 0 versus III and IV                                       3.00 3.76 5.84   1.773 2.359 4.257   0.943, 9.554 1.102, 12.858 1.399, 24.372    1.86 2.12 2.42    0.063 0.034 0.015
  SLNB                                                                                                                     0.40              0.137                       0.206, 0.784                      −2.67               0.007
  Number of nodes removed                                                                                                  1.08              0.021                       1.043, 1.126                       4.10              \<.0001
  Any chemotherapy                                                                                                         1.20              0.368                       0.654, 2.184                       0.58               0.561
  Any radiation therapy                                                                                                    1.32              0.390                       0.738, 2.356                       0.93               0.351
  Self-reported race/ethnicity White versus Black White versus Asian/Pacific Islander White versus Hispanic/Mixed     4.35 2.90 2.35   4.880 2.693 1.290   0.483, 39.201 0.472, 17.875 0.798, 6.890    1.31 1.15 1.55    0.190 0.250 0.121
  Genomic race/ethnicity AIMS -- Principal component 1 AIMS -- Principal component 2 AIMS -- Principal component 3    0.75 0.86 1.10   0.121 0.104 0.122    0.549, 1.030 0.678, 1.090 0.886, 1.367    −1.78 −1.25 0.87   0.076 0.211 0.386
  Overall model fit: χ^2^ = 77.83, p\<0.0001, R^2^ = 0.1735                                                                                                                                                             

Abbreviations: AIMS  =  ancestry informative markers; BMI  =  body mass index; CI  = confidence interval; SLNB  =  sentinel lymph node biopsy.

In the second regression analysis that added genomic estimates of and self-reported race/ethnicity in addition to the characteristics listed above, the overall model explained 17.4% of the variance in LE group membership (p\<0.0001). While BMI, stage of disease, SLNB status, and number of lymph nodes removed remained significant, when genomic and self-reported race/ethnicity were included in the model, the receipt of CTX and RT were no longer significant predictors of LE group membership.

Candidate gene analyses for the development of LE {#s3c}
-------------------------------------------------

As summarized in [Table 1](#pone-0060164-t001){ref-type="table"}, no associations with the occurrence of LE were found in the SNPs evaluated for HGF, LYVE1, MET, PROX1, RORC, VEGFB, VEGFD, and VEGFR3. However, the genotype frequency was significantly different between those who did and did not develop LE for thirteen SNPs and seven haplotypes spanning nine genes (i.e., ANGPT2, FOXC2, LCP2, NRP2, SOX 17, SYK, VCAM1, VEGFC, and VEGFR2). For the SNP in ANGPT2 (rs6990020), a dominant model fit the data best (p = .040). One haplotype (HapA03, p = .045) was identified in FOXC2. For the three SNPs (rs572192, rs315721, rs6866733) identified in LCP2, a dominant model fit the data best (p = .047, p = .005, p = .026, respectively). Three SNPs (rs849530, rs849563, rs16837641) and one haplotype (HapF01, p = .011) were identified in NRP2. For all three SNPs, a recessive model fit the data best (p = .042, p = .012, p = .009, respectively). For the SNP in SOX17 (rs12541742), a dominant model fit the data best (p = .008). One SNP (rs158689) and 1 haplotype (HapD01, p = .008) were identified in SYK. For rs158689, a recessive model fit the data best (p = .039). One SNP (rs3176861) and one haplotype (HapB01, p = .016) were identified in VCAM1. For rs3176861, a dominant model fit the data best (p = .036). One SNP (rs7664413) and two haplotypes (HapA05, p = .046; HapB03, p = .027) were identified in VEGFC. For rs7664413, an additive model fit the data best (p = .041). Two SNPs (rs10020464, rs11133360) and one haplotype (HapC04, p = .021) were identified for VEGFR2. For rs10020464, a dominant model fit the data best (p = .025) and for rs11133360 a recessive model fit the data best (p = .032).

Regression analyses of FOXC2, LCP2, NRP2, SYK, VCAM1, and VECFC genotypes and haplotypes and the development of LE {#s3d}
------------------------------------------------------------------------------------------------------------------

In order to better estimate the magnitude (i.e., odds ratio, OR) and precision (95% confidence interval, CI) of genotype on the development of LE, multivariate logistic regression models were fit. As shown in [Table 4](#pone-0060164-t004){ref-type="table"}, in addition to genotype, the phenotypic variables included in the regression models were ethnicity (i.e., White, Black, Asian, Hispanic/Mixed ethnic background/Other), BMI, stage of disease, having a SLNB, and number of lymph nodes removed. Receipt of CTX and RT, while not significant after the inclusion of genomic estimates of and self-reported race/ethnicity, were retained in all of the regression models for face validity.

10.1371/journal.pone.0060164.t004

###### Multiple logistic regression analyses for FOXC2. LCP2, NRP2, SYK, VCAM1, and VEGF-C genotypes and halotypes to predict the development of lymphedema.
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  Predictor                                                                          Odds Ratio      Standard Error                      95% CI                           Z               p-value
  ------------------------------------------------------------------------------- ---------------- ------------------- ------------------------------------------- ---------------- -------------------
  FOXC2 haplotype                                                                       0.63              0.125                       0.430, 0.931                      −2.32              0.020
  BMI                                                                                   1.06              0.022                       1.016, 1.104                       2.72              0.006
  Stage of disease Stage 0 versus I Stage 0 versus II Stage 0 versus III and IV    3.43 4.10 6.71   2.053 2.619 4.975   1.060, 11.085 1.175, 14.333 1.571, 28.687   2.06 2.21 2.57   0.040 0.027 0.010
  SLNB                                                                                  0.40              0.138                       0.203, 0.784                      −2.67              0.008
  Number of nodes removed                                                               1.08              0.022                       1.042, 1.127                       4.01             \<.0001
  Any chemotherapy                                                                      1.22              0.380                       0.664, 2.246                       0.64              0.521
  Any radiation therapy                                                                 1.35              0.406                       0.752, 2.436                       1.01              0.313
  Overall model fit: χ^2^ = 83.44, p\<0.0001, R^2^ = 0.1860                                                                                                                         
  LCP2 genotype                                                                         0.50              0.132                       0.298, 0.838                      −2.63              0.009
  BMI                                                                                   1.05              0.022                       1.012, 1.097                       2.54              0.011
  Stage of disease Stage 0 versus I Stage 0 versus II Stage 0 versus III and IV    3.01 3.56 5.94   1.788 2.238 4.365   0.937, 9.643 1.040, 12.203 1.407, 25.079    1.85 2.02 2.42   0.064 0.043 0.015
  SLNB                                                                                  0.40              0.137                       0.204, 0.784                      −2.67              0.008
  Number of nodes removed                                                               1.08              0.022                       1.040, 1.125                       3.93             \<.0001
  Any chemotherapy                                                                      1.25              0.389                       0.679, 2.298                       0.71              0.475
  Any radiation therapy                                                                 1.33              0.398                       0.744, 2.392                       0.97              0.334
  Overall model fit: χ^2^ = 84.86, p\<0.0001, R^2^ = 0.1891                                                                                                                         
  NRP2 genotype                                                                         0.38              0.143                       0.185, 0.799                      −2.56              0.010
  BMI                                                                                   1.06              0.023                       1.016, 1.105                       2.68              0.007
  Stage of disease Stage 0 versus I Stage 0 versus II Stage 0 versus III and IV    2.79 3.41 6.01   1.647 2.150 4.430   0.874, 8.875 0.990, 11.733 1.420, 25.477    1.73 1.94 2.44   0.083 0.052 0.015
  SLNB                                                                                  0.39              0.136                       0.203, 0.775                      −2.71              0.007
  Number of nodes removed                                                               1.08              0.021                       1.040, 1.122                       4.00            \<0.0001
  Any chemotherapy                                                                      1.18              0.369                       0.635, 2.174                       0.51              0.607
  Any radiation therapy                                                                 1.20              0.363                       0.667, 2.171                       0.61              0.539
  Overall model fit: χ^2^ = 85.11, p\<0.0001, R^2^ = 0.1897                                                                                                                         
  NRP2 haplotype                                                                        0.54              0.114                       0.358, 0.817                      −2.92              0.003
  BMI                                                                                   1.05              0.022                       1.011, 1.099                       2.48              0.013
  Stage of disease Stage 0 versus I Stage 0 versus II Stage 0 versus III and IV    3.03 3.81 5.49   1.805 2.433 4.081   0.941, 9.738 1.088, 13.321 1.281, 23.561    1.86 2.09 2.29   0.063 0.036 0.022
  SLNB                                                                                  0.40              0.137                       0.201, 0.780                      −2.68              0.007
  Number of nodes removed                                                               1.09              0.021                       1.046, 1.132                       4.21            \<0.0001
  Any chemotherapy                                                                      1.11              0.348                       0.602, 2.054                       0.34              0.734
  Any radiation therapy                                                                 1.30              0.391                       0.723, 2.346                       0.88              0.379
  Overall model fit: χ^2^ = 86.91, p\<0.0001, R^2^ = 0.1937                                                                                                                         
  SYK genotype                                                                          3.43              1.131                       1.797, 6.546                       3.74            \<0.0001
  BMI                                                                                   1.06              0.023                       1.017, 1.106                       2.76              0.006
  Stage of disease Stage 0 versus I Stage 0 versus II Stage 0 versus III and IV    3.05 3.10 5.50   1.821 1.968 4.078   0.946, 9.832 0.891, 10.760 1.286, 23.523    1.87 1.78 2.30   0.062 0.075 0.022
  SLNB                                                                                  0.40              0.141                       0.201, 0.797                      −2.61              0.009
  Number of nodes removed                                                               1.10              0.022                       1.054, 1.142                       4.53            \<0.0001
  Any chemotherapy                                                                      1.44              0.459                       0.773, 2.692                       1.15              0.249
  Any radiation therapy                                                                 1.45              0.437                       0.803, 2.616                       1.23              0.218
  Overall model fit: χ^2^ = 91.90, p\<0.0001, R^2^ = 0.2049                                                                                                                         
  VCAM1 genotype                                                                        0.55              0.158                       0.309, 0.963                      −2.09              0.037
  BMI                                                                                   1.06              0.022                       1.015, 1.102                       2.68              0.007
  Stage of disease Stage 0 versus I Stage 0 versus II Stage 0 versus III and IV    2.85 3.78 5.92   1.710 2.413 4.385   0.879, 9.239 1.080, 13.214 1.388, 25.275    1.75 2.08 2.40   0.081 0.038 0.016
  SLNB                                                                                  0.41              0.141                       0.206, 0.801                      −2.60              0.009
  Number of nodes removed                                                               1.08              0.022                       1.043, 1.128                       4.07            \<0.0001
  Any chemotherapy                                                                      1.18              0.365                       0.643, 2.161                       0.53              0.596
  Any radiation therapy                                                                 1.30              0.387                       0.724, 2.327                       0.88              0.381
  Overall model fit: χ^2^ = 82.35, p\<0.0001, R^2^ = 0.1836                                                                                                                         
  VEGFC haplotype                                                                       0.64              0.145                       0.409, 0.997                      −1.97              0.049
  BMI                                                                                   1.05              0.022                       1.011, 1.097                       2.46              0.014
  Stage of disease Stage 0 versus I Stage 0 versus II Stage 0 versus III and IV    2.94 3.74 5.42   1.740 2.351 3.962   0.920, 9.380 1.091, 12.820 1.291, 22.716    1.82 2.10 2.31   0.069 0.036 0.021
  SLNB                                                                                  0.42              0.145                       0.215, 0.826                      −2.51              0.012
  Number of nodes removed                                                               1.09              0.021                       1.044, 1.128                       4.16            \<0.0001
  Any chemotherapy                                                                      1.24              0.387                       0.675, 2.287                       0.70              0.487
  Any radiation therapy                                                                 1.31              0.391                       0.729, 2.354                       0.90              0.366
  Overall model fit: χ^2^ = 81.85, p\<0.0001, R^2^ = 0.1825                                                                                                                         

For each model, the first three principal components identified from the analysis of ancestry informative markers as well as self-report race/ethnicity (i.e., White, Black, Asian/Pacific Islander, Hispanic/Mixed ethnic background/Other) were retained in all models to adjust for potential confounding due to race or ethnicity (data not shown). Predictors evaluated in each model included genotype (FOXC2 haplotype A03 composed of the rs34221221 "C" allele and the rs1035550 "C" allele; LCP2 rs315721: AA versus AG+GG; NRP2 rs849530: TT+TG versus GG; NPR2 haplotype F01 composed of the rs849530 "G" allele, the rs950219 "G" allele, and the rs3771052 "G" allele; SYK rs158689: AA+AT versus TT; VCAM1 rs3176861: CC versus CT + TT; VEGFC haplotype B03 composed of the rs3775202 "G" allele and the rs3775195 "C" allele), BMI (kilograms/meter squared), stage of disease, SLNB, number of lymph nodes removed, receipt of chemotherapy prior to or following surgery, and receipt of radiation therapy following surgery.

Abbreviations: BMI  =  body mass index; CI  = confidence interval; FOXC2  =  Forkhead box protein C2; LCP2  =  Lymphocyte cytosolic protein 2; NRP  =  neuropilin-2; SLNB  =  sentinel lymph node biopsy; SYK  =  spleen tyrosine kinase; VCAM1  =  vascular cell adhesion molecule 1; VEGFC  =  vascular endothelial growth factor-C.

The only genetic associations that remained significant in the multivariate logistic regression analyses were for FOXC2 haplotype A03, LCP2 rs315721, NRP2 rs849530, NRP2 haplotype F01, SYK rs158689, VCAM1 rs3176861, and VEGFC haplotype B03 (see [Table 4](#pone-0060164-t004){ref-type="table"} and [Figures 1](#pone-0060164-g001){ref-type="fig"}, [2](#pone-0060164-g002){ref-type="fig"}, [3](#pone-0060164-g003){ref-type="fig"}, and [4](#pone-0060164-g004){ref-type="fig"}). In the regression analysis for the FOXC2 haplotype A3, which was composed of two SNPs (i.e., rs34221221, rs1035550), the overall model explained 18.6% of the variance in the odds of developing LE. Each additional dose of the FOXC2 haplotype A03 was associated with 37.0% decrease in the odds of developing LE. [Figure 1](#pone-0060164-g001){ref-type="fig"} displays the FOXC2 LD-based heatmap and haplotype analysis.

![FOXC2 Gene Structure and Linkage Disequilibrium.\
An ideogram of forkhead box C2 (FOXC2) is presented above the white bar that represents the physical distance along human chromosome 16 (chr16: 85,158,358--85,160,040; genome assembly 36.3, NM_005251.2). Exons are represented as thick bars. Reference sequence identifiers (rsID) for each single nucleotide polymorphism (SNP) are plotted both in terms of their physical distance (i.e., the white bar at the top of the figure) and equidistantly to render the pairwise linkage disequilibrium (LD) estimates that were calculated and visualized with Haploview 4.2. The gene structure for FOXC2 was rendered with FancyGene 1.4. The correlation statistic (r^2^ and D\') is provided in the heatmap. LD-based haplotype block definition was based on the D\' confidence interval method. The haploblock is indicated in a bolded triangle and its component SNPs are rendered in bold font. Pairwise D\' value (range: 0--1, inclusive) was rendered in color, with darker red diamond representing D\' value approaching 1.0. When the r^2^ value (range of 0--100, inclusive) is not equal to 0 or 100, it is provided in a given diamond. The 2-SNP haplotype associated with LE is composed of one rare and one common allele of two SNPs located in the immediate early promoter (rs34221221; rare "C" allele) and immediately downstream of the FOXC2 coding region (rs1035550; common "C" allele).](pone.0060164.g001){#pone-0060164-g001}

![Differences between the lymphedema and no lymphedema groups.\
A -- Differences between the lymphedema and no lymphedema groups in the percentages of patients who were homozygous for the common allele (AA) or heterozygous or homozygous for the rare allele (AG+GG) for rs315721 in lymphocyte cytosolic protein 2 (LCP2). B -- Differences between the lymphedema and no lymphedema groups in the percentages of patients who were homozygous or heterozygous for the common allele (TT+TG) or homozygous for the rare allele (GG) for rs849530 in neuropilin-2 (NRP2). C -- Differences between the lymphedema and no lymphedema groups in the percentages of patients who were homozygous or heterozygous for the common allele (AA+AT) or homozygous for the rare allele (TT) for rs158689 in protein tyrosine kinase (SYK). D -- Differences between the lymphedema and no lymphedema groups in the percentages of patients who were homozygous for the common allele (CC) or heterozygous or homozygous for the rare allele (CT+TT) for rs3176861 in vascular cell adhesion molecule 1 (VCAM1).](pone.0060164.g002){#pone-0060164-g002}

![NRP2 Gene Structure and Linkage Disequilibrium.\
An ideogram of neuropilin 2 (NRP2) is presented above the white bar that represents the physical distance along human chromosome 2 (chr2: 206,255,469--206,371,102; genome assembly 36.3, NM_201266.1). Exons are represented as thick bars. Gray lines connecting the exons represent introns. Reference sequence identifiers (rsID) for each single nucleotide polymorphism (SNP) are plotted both in terms of their physical distance (i.e., the white bar at the top of the figure) and equidistantly to render the pairwise linkage disequilibrium (LD) estimates that were calculated and visualized with Haploview 4.2. The gene structure for NRP2 was rendered with FancyGene 1.4. The correlation statistics (r^2^ and D\') are provided in the heatmap. LD-based haplotype block definition was based on the D\' confidence interval method. The haploblock is indicated in a bolded triangle and its component SNPs are rendered in bold font. Pairwise D\' values (range: 0--1, inclusive) were rendered in color, with darker red diamonds representing D\' values approaching 1.0. When the r^2^ values (range of 0--100, inclusive) are not equal to 0 or 100, they are provided in a given diamond. The 3-SNP haplotype associated with LE consists of one rare and two common alleles of three SNPs (rs849530 "G" rare allele, rs950219 "G" common allele, rs3771052 "G" common allele) located in intron 1 of the gene.](pone.0060164.g003){#pone-0060164-g003}

![VEGFC Gene Structure and Linkage Disequilibrium.\
An ideogram of vascular endothelial growth factor C (VEGFC) is presented above the white bar that represents the physical distance along human chromosome 4 (chr4: 177,841,685--177,950,889; genome assembly 36.3, NM_005429.2). Exons are represented as thick bars. Gray lines connecting the exons represent introns. Reference sequence identifiers (rsID) for each single nucleotide polymorphism (SNP) are plotted both in terms of their physical distance (i.e., the white bar at the top of the figure) and equidistantly to render the pairwise linkage disequilibrium (LD) estimates that were calculated and visualized with Haploview 4.2. The gene structure for VEGFC was rendered with FancyGene 1.4. The correlation statistics (r^2^ and D\') are provided in the heatmap. LD-based haplotype block definition was based on the D\' confidence interval method. The haploblock is indicated in a bolded triangle and its component SNPs are rendered in bold font. Pairwise D\' values (range: 0--1, inclusive) were rendered in color, with darker red diamonds representing D\' values approaching 1.0. When the r^2^ values (range of 0--100, inclusive) are not equal to 0 or 100, they are provided in a given diamond. The 2-SNP haplotype associated with LE consists of one rare and one common allele of two SNPs (rs3775202 "G" rare allele, rs3775195 "C" common allele) located in intron 4 of the gene. Of note, the strong linkage disequilibrium estimates observed in public databases (i.e., HapMap) resulted in the selection of 8 SNPs that tagged the entire coding region of the VEGFC gene.](pone.0060164.g004){#pone-0060164-g004}

In the regression analysis for LCP2 rs315721, the overall model explained 18.9% of the variance in the odds of developing LE. Carrying one or two doses of the rare allele (i.e., AA versus AG + GG) was associated with a 50.0% decrease in the odds of developing LE ([Figure 2A](#pone-0060164-g002){ref-type="fig"}).

In the regression analysis for NRP2 rs849530, the overall model explained 19.0% of the variance in the odds of developing LE. Carrying two doses of the rare allele (i.e., TT+TG versus GG) was associated with 62.0% decrease in the odds of developing LE ([Figure 2B](#pone-0060164-g002){ref-type="fig"}). In the regression analysis for the NRP2 haplotype F01, which was composed of three SNPs (i.e., rs849530, rs950219, rs3771052), the overall model explained 19.4% of the variance in the odds of developing LE. Each additional dose of the NRP2 haplotype F01 was associated with 46.0% decrease in the odds of developing LE. [Figure 3](#pone-0060164-g003){ref-type="fig"} displays the NRP2 LD-based heatmap and haplotype analysis.

In the regression analysis for SYK rs158689, the overall model explained 20.1% of the variance in the odds of developing LE. Carrying two doses of the rare allele (i.e., AA + AT versus TT) was associated with 3.43-fold increase in the odds of developing LE ([Figure 2C](#pone-0060164-g002){ref-type="fig"}).

In the regression analysis for VCAM1 rs3176861, the overall model explained 18.4% of the variance in the odds of developing LE. Carrying one or two doses of the rare allele (i.e., CC versus CT + TT) was associated with a 45.0% decrease in the odds of developing LE ([Figure 2D](#pone-0060164-g002){ref-type="fig"}).

In the regression analysis for the VEGFC haplotype B03, which was composed of two SNPs (i.e., rs3775202, rs3775195), the overall model explained 18.3% of the variance in the odds of developing LE. Each additional dose of the VEGFC haplotype B03 was associated with 36.0% decrease in the odds of developing LE. [Figure 4](#pone-0060164-g004){ref-type="fig"} displays the VEGFC LD-based heatmap and haplotype analysis.

Discussion {#s4}
==========

This study is the first to evaluate phenotypic and genotypic predictors of LE in a large cohort of women who had LE diagnosed using BIS rather than self-report. Based on an extensive evaluation of demographic, disease, and treatment characteristics, the factors associated with an increased risk of LE in the bivariate analyses were higher BMI, poorer functional status, having lung disease, a higher stage of disease, increased number of lymph nodes removed, increased number of positive lymph nodes, not having a SLND, having had an ALND, and receipt of CTX or RT. All of these risk factors are consistent with previous reports.

In the initial multivariate analyses, poorer functional status, having lung disease, number of positive nodes, and having had an ALND were not retained in the final model ([Table 3](#pone-0060164-t003){ref-type="table"}). However, when genomic estimates of and self-reported race/ethnicity were added to the multivariate logistic regression analysis, receipt of CTX and RT were no longer significant predictors of LE group membership. This final phenotypic model explained only 17.4% of the variance in LE group membership. These findings suggest that complex interactions may exist between phenotypic characteristics and the development of LE. Future studies of LE risk need to evaluate a comprehensive list of phenotypic characteristics as well as interactions among these characteristics.

In the past few years, the complex array of molecular events that regulate the development and maintenance of lymphatic system, as well as contribute to its malfunction have begun to be elucidated in animals and humans [@pone.0060164-SchulteMerker1], [@pone.0060164-Wang1], [@pone.0060164-Butler1]. In this study, candidate genes were selected that were identified in previous animal and human studies to play a role in lymphatic morphogenesis ([Table 1](#pone-0060164-t001){ref-type="table"}). While not all of the candidate genes were associated with the development of LE, the significant associations that were identified provide new information on genomic risk factors and potential therapeutic targets. Of note, each of the SNPs explained between 1.0% (VCAM1 rs3176861) to 3.1% (SYK rs158689) of the variance in the development of LE.

FOXC2 is a transcription factor that appears to be important for the normal development and maintenance of both venous and lymphatic vessels [@pone.0060164-Mellor1]. In adults, FOXC2 is highly expressed in developing lymphatic vessels as well as in lymphatic valves [@pone.0060164-Petrova1], [@pone.0060164-Dagenais1]. While early lymphatic development will proceed normally in the absence of FOXC2, the collecting lymphatic vessels that are formed lack valves and the lymphatic capillaries acquire an ectopic coverage of basement membrane components and smooth muscle cells [@pone.0060164-Petrova1]. FOXC2 is the transcription factor associated with lymphedema-distichiasis (LD, OMIM \#153400) a monogenic disorder that is characterized by late onset LE, a double row of eyelashes, and varicose veins [@pone.0060164-Fang1]--[@pone.0060164-Connell1]. Therefore, common functional polymorphisms that result in modest alterations in function or expression of the FOXC2 transcription factor may be associated with the development of secondary LE following breast cancer treatment. The FOXC2 A03 haplotype consists of one rare and one common allele in two SNPs located in the immediate early promoter (rs34221221; rare "C" allele) and immediately downstream from the FOXC2 coding region (rs1035550, common "C" allele). SNP rs34221221 occurs in the immediate early promoter of the FOXC2 gene (−514) which is a highly conserved region of the gene. While functional studies need to be done, it is reasonable to suggest that this polymorphism alters transcription factor binding and subsequent gene expression. SNP rs103550 lies downstream from the FOXC2 coding region of the gene and is not likely to have a functional role. Functional studies of this two-SNP haplotype are warranted if the association with LE is replicated in an independent sample.

LCP2 functions in lymphatic vessel development by modulation of the hematopoetic signaling pathway that mediates the separation of the two major vascular networks (i.e., blood, lymphatic) [@pone.0060164-Abtahian1]. SYK acts on LCP2 as part of a central signaling pathway that regulates separation of these two vascular networks. Variation in either locus could result in their altered interaction with upstream (i.e., SYK) or downstream (i.e., LCP2) members of the signaling cascade. Mice with mutations in SYK develop arterio-venous shunts and abnormal lymphatic-venous connections [@pone.0060164-Abtahian1], [@pone.0060164-Sebzda1]. In addition, genetic ablation of SYK causes the accumulation of leukocytes that is associated with lymphatic proliferation and lymphatic vessel dilation which results in the formation of shunts between the blood and lymphatic vessels (F. Kiefer, personal communication cited in Tammela and Alitalo [@pone.0060164-Tammela1]). While LPC2 rs35721 is located in the intronic region of the gene and has no known function, it could be in LD with a functional variation. Although SYK rs158689 is located in an intron, it is predicted to disrupt a putative CCCTC-binding factor (CTCF) termed insulator elements. These insulator elements play a vital role in the regulation of gene expression by limiting the boundary of heterochromatin and by restricting transcriptional factor access [@pone.0060164-Dhruva1]. Functional studies are needed to determine if the rare "T" allele of rs158689 alters the function of the putative insulator element and SYK gene expression.

Lymphatic vessels participate in inflammatory responses by promoting lymphocyte transport to draining lymph nodes [@pone.0060164-Kerjaschki1]. VCAM1 plays a role in the migration of lymphocytes into lymphoid organs. Compared to healthy controls, cytokines levels are increased in lymphatic fluid from patients with obstructive LE. These elevated levels of cytokines may be due to their local production by infiltrating immune cells [@pone.0060164-Olszewski1]. The elevated levels of these cytokines would be expected to contribute to the chronic inflammation that is typically observed in tissues with poor lymphatic drainage. Allelic variations in VCAM1 could influence the rate of lymphocyte homing to lymph nodes. Like other SNPs in this study, rs3176861, located in the intron of the VCAM gene, has no known function. However, it could be in LD with a functional variation.

NRP1 and NRP2 are transmembrane proteins involved in a number of physiologic processes [@pone.0060164-Chen1]--[@pone.0060164-Karpanen1]. NRP2 can bind to members of the VEGF family of growth factors and influence lymphagiogenesis. NRP2 is expressed in a subset of lymphatic vessels and acts as a co-receptor for VEGFC [@pone.0060164-Karkkainen1]. VEGFC binds to and activates VEGFR3 and VEGFR2 receptors on the lymphatic epithelium [@pone.0060164-Joukov1]--[@pone.0060164-Achen1]. In one study [@pone.0060164-Yuan1], *Nrp2* knockout mice did not exhibit defects in blood vessels. However, lymphatic development was abnormal, including abnormal patterning and marked reduction in small lymphatic vessels and capillaries. These findings suggest that NRP2 has a role in VEGFC mediated VEGFR3 signaling and lymphangiogenesis. The NRP2 haplotype consists of one rare and two common alleles in three SNPs (rs849530 "G" rare allele, rs950219 "G" common allele, rs3771052 "G" common allele) located in intron 1 of the gene. These SNPs lie in a conserved region of the NRP2 gene. However, this haplotype has no known function which suggest that this haplotype is a surrogate for an unmeasured SNP(s) in LD with the haplotype. The VEGFC haplotype consists of one rare and one common allele in two SNPs (rs3775202 "G" rare allele, rs3775195 "C" common allele) located in intron 4 of the gene. These SNPs lie in a conserved region of the VEGFC gene. However, this haplotype has no known or predicted function which suggests that it is a surrogate for an unmeasured SNP(s) in LD with this haplotype.

It is interesting to note that no associations were found in SNPs for HGF, LYVE1, MET, PROX1, RORC, VEGFB, VEGFC, and VEGFR3. One possible reason for this lack of association is that these genes are involved primarily during embryogenesis in the development of the lymphatic system and are not involved in the mechanisms that underlie the development of secondary LE [@pone.0060164-SchulteMerker1], [@pone.0060164-Wang1], [@pone.0060164-Butler1]. However, recent evidence suggests that the VEGF pathway is involved in lymphangiogenesis associated with inflammation [@pone.0060164-Tammela1], [@pone.0060164-Alitalo1]. An alternative explanation for the lack of association is that the occurrence of the minor allele was too infrequent in this sample to identify significant differences between patients with and without LE. Evidence to support this hypothesis is found in [Table 1](#pone-0060164-t001){ref-type="table"}, where p-values for some of these genes approached statistical significance.

Several study limitations need to be acknowledged. While the sample size was relatively large, larger samples may identify additional candidate gene associations. In terms of the genetic analyses, additional studies are needed to confirm the associations found in this study. Future studies can evaluate additional candidate genes or perform genome wide association studies to uncover novel molecular pathways. Once candidate genes are confirmed, then DNA sequencing may need to be performed to find the causal variant(s). Despite these limitations, findings from this study suggest a role for a number of lymphatic and angiogenic candidate genes in the development of secondary LE following breast cancer treatment.
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